REGISTER BY OCTOBER 30 AND SAVE UP TO $350!
Plus, qualify for a 23andMe Custom Genome Scan.

Cambridge Healthtech Institute's


Track 3 at CHI's
Molecular Medicine
Tri-Conference

View the agenda

TheStemCellsCongress.com
Pre-Conference Short Course*
Tuesday, February 24, 2009

CURRENT COMMERCIAL CONSIDERATIONS
FOR CELL-BASED THERAPIES

This course will review key considerations,
strategies, and pivotal tactics for companies
commercializing cell therapeutics and/or
products that will be employed in that market.
This course will be primarily designed for
corporate executives, entrepreneurs, and
investors.
Topics to be covered:
- An overview of the (current) cell therapy,
regenerative medicine, and cells-as-tools
market

- Developing and implementing a clinical
development strategy that positions a
product for optimal reimbursement at or
near the time of product launch

- A review of key challenges facing the
industry and how they will/must be
addressed

- A perspective on the role of various
industry stakeholders including device,
platform, reagent, investment, service,
insurers, clinicians, and therapeutic
companies.
Course Instructors:
Lee Buckler, Bed, LLB, Principal, Cell Therapy
Group

Dawn Driscoll, Ph.D, M.B.A., Principal,
DCi Biotech


For sponsorship and exhibit
opportunities, contact
Carol Dinerstein
781-972-5471
dinerstein@healthtech.comJon Stroup
781-972-5483
jstroup@healthtech.com


Click here for details

Address the topics central to the theme of regenerative medicine

Network with prominent researchers, clinicians, businessmen and regulators at the
cutting edge of their respective fields

Develop strategies to enable the rapidly expanding therapeutic potential of
regenerative medicine

SESSION TOPICS INCLUDE - View agenda

- The Stem Cell Niche
- Controlling and Understanding Differentiation
- Therapeutic Themes: Considerations for Cardia Regeneration
- Harnessing Cells For Regenerative Healing
- Therapeutic Themes: iPS Cells and Personalized Medicine
New! Venture Capital and Emerging Company Forum




Scientific Advisory Committee
- Lee Buckler, LLB, Business Development, Progenitor Cell Therapy

- Robert Deans, Ph.D., Senior Vice President, Regenerative Medicine, Athersys, Inc.

- Rosemarie Hunziker, Ph.D., Program Director, Tissue Engineering & Regenerative
Medicine, NIH/NIBIB

- Mark E. Levenstein, Ph.D., Senior Scientist, CDI Biosciences

- Patricia Olson, Ph.D., Senior Research Scientist, California Institute of Regenerative
Medicine

- Deepak Srivastava, M.D., Gladstone Institute of Cardiovascular Disease, University
of California San Francisco


Co-Sponsors